Evidence map›Paper›PMID 21872802›Full record

ArticleBest practice & research. Clinical endocrinology & metabolism2011

Vitamin D and cancer: clinical aspects.

Anna Woloszynska-Read, Candace S Johnson, Donald L Trump

Open access · greenAbstract read
In one paragraph

Article in Best practice & research. Clinical endocrinology & metabolism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Vitamin D supplementation for prevention of cancer in adults.The Cochrane database of systematic reviews · 2014
    Pooled it
  2. Review
  3. Exploring the Molecular Mechanism of 1,25(OH)Current issues in molecular biology · 2025
    Article
  4. Review
  5. Emerging perspectives: unraveling the anticancer potential of vitamin DNaunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  6. Review
  7. Serum Level of Vitamin D in Patients with Salivary Gland Tumors.Iranian journal of otorhinolaryngology · 2023
    Article
  8. Article
  9. Micro-RNAs in Response to Active Forms of Vitamin DInternational journal of molecular sciences · 2022
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Anna Woloszynska-ReadDepartment of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Candace S Johnson
Donald L Trump
Roswell Park Comprehensive Cancer Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Christine B. Ambrosone · 1985 to 2026
$116.6M
ANTITUMOR MECHANISMS &THERAPEUTIC EFFECTS OF VITAMIN DR01CA067267 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHNSON, CANDACE S, TRUMP, DONALD L · 1995 to 2013
$5.7M
GLUCOCORTICOIDS &VITAMIN D: ROLE IN ANTI-TUMOR EFFECTSR01CA085142 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHNSON, CANDACE S · 2000 to 2009
$3.3M
Vitamin D in Prostate Cancer: Tumor Vasculature EffectsR01CA095045 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI JOHNSON, CANDACE S · 2002 to 2012
$3.2M
Interdisciplinary Training in Cancer Epidemiology at UBR25CA113951 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI FREUDENHEIM, JO L., MOYSICH, KIRSTEN B. · 2007 to 2016
$2.5M
NCI NIH HHS 5P30 CA016056-34NCI NIH HHS 5R01 CA067267-17NCI NIH HHS 5R01 CA085142-10NCI NIH HHS 5R01 CA095045-08NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA067267NCI NIH HHS R01 CA085142NCI NIH HHS R01 CA095045NCI NIH HHS R25 CA113951NCI NIH HHS R25CA113951-01
6 · The paper itself

Abstract

There are substantial preclinical and epidemiologic data that suggest that vitamin D plays a role in the prevention and treatment of cancer. Numerous observational studies have shown that low blood levels of 25(OH) vitamin D (cholecalciferol), estimated by geographical location, diet and activity assessment or measured serum levels are associated with a higher risk of cancer and worse cancer-specific survival as well as numerous morbidities to e.g. cardiovascular disease, stroke, infection, autoimmune disease, and neuromuscular dysfunction among large populations. A considerable number of in vitro and in vivo studies indicate that the most active metabolite of vitamin D--1,25-dihydroxycholecalciferol or calcitriol--has anti-proliferative, pro-apoptotic, pro-differentiating, and anti-angiogenic properties. Combined treatment of calcitriol and many types of cytotoxic agents has synergistic or at least additive effects. However, clinical trials testing these hypotheses have been less encouraging, though a number of methodological, pharmacological, and pharmaceutical issues confound all trials ever conducted. In order to properly assess the clinical value of vitamin D, its metabolites and analogs in cancer prevention and treatment, more studies are needed.

Indexed as

AnimalsAnticarcinogenic AgentsAntineoplastic AgentsCalcitriolCholecalciferolHumansNeoplasmsVitamin DVitamin D DeficiencyAnticarcinogenic AgentsAntineoplastic AgentsCalcitriolCholecalciferolVitamin D

Identifiers

PMID21872802
PMCPMC4729360
OpenAlexW1971449474

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.